Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Free Subscription


4 Acta Haematol
1 Am J Hematol
3 Ann Hematol
3 Blood
1 Exp Hematol
3 Int J Hematol
1 J Biol Chem
1 J Clin Oncol
1 J Natl Cancer Inst
1 J Pediatr Hematol Oncol
2 Leuk Lymphoma
2 Leuk Res
5 Leukemia
1 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Acta Haematol

  1. PAN L, Zheng Y, Zheng H
    Long Non-coding RNA RP11-252C15.1 is a Potential Biomarker of Prognosis and Hallmark for Leukemogenesis in Children with B-cell Precursor Acute Lymphoblastic Leukemia.
    Acta Haematol. 2024 Mar 25. doi: 10.1159/000535461.
    PubMed         Abstract available

  2. CARLSON KS, Cunningham A, Stahl M, Winer E, et al
    Diagnostic Precision or Pitfalls: How to Apply the New Acute Myeloid Leukemia Classification Systems?
    Acta Haematol. 2024;147:122-132.
    PubMed         Abstract available

  3. JIMENEZ-CHILLON C, Dillon R, Russell N
    Optimal Post-Remission Consolidation Therapy in Patients with AML.
    Acta Haematol. 2024;147:147-158.
    PubMed         Abstract available

  4. BUCHRITS S, Wolach O
    Non-Immunotherapy Approaches for Relapsed or Refractory AML: An Update for 2024.
    Acta Haematol. 2024;147:159-174.
    PubMed         Abstract available

    Am J Hematol

  5. HADDAD FG, Sasaki K, Issa GC, Jabbour E, et al
    The presence of additional cytogenetic abnormalities (ACAs) or Philadelphia chromosome variants do not adversely affect the achievement of treatment-free remission in chronic myeloid leukemia.
    Am J Hematol. 2024 Mar 28. doi: 10.1002/ajh.27307.

    Ann Hematol

  6. CHEN Y, Pan M, Chen L, Peng M, et al
    Correction to: Identification of a novel fusion gene, RARA::ANKRD34C, in acute promyelocytic leukemia.
    Ann Hematol. 2024 Mar 27. doi: 10.1007/s00277-024-05675.

  7. WU CY, Yeh CM, Tsai CK, Liu CJ, et al
    The influence of hospital volume and physician volume on early mortality in acute promyelocytic leukemia patients.
    Ann Hematol. 2024 Mar 26. doi: 10.1007/s00277-024-05616.
    PubMed         Abstract available

  8. CAI X, Liu Y, Li H, Que Y, et al
    XPO1 inhibition displays anti-leukemia efficacy against DNMT3A-mutant acute myeloid leukemia via downregulating glutathione pathway.
    Ann Hematol. 2024 Mar 23. doi: 10.1007/s00277-024-05706.
    PubMed         Abstract available


  9. INESS AN, Bachireddy P
    GPR56 in GVL: marker or mechanism?
    Blood. 2024;143:1206-1207.

  10. MATHIOUDAKI A, Wang X, Sedloev D, Huth R, et al
    The remission status of AML patients after allo-HCT is associated with a distinct single-cell bone marrow T-cell signature.
    Blood. 2024;143:1269-1281.
    PubMed         Abstract available

  11. XIE J, Bao X, Xue SL, Shen H, et al
    Venetoclax with decitabine as frontline treatment in younger adults with newly diagnosed ELN adverse-risk AML.
    Blood. 2023;142:1323-1327.

    Exp Hematol

  12. GOSWAMI M, Bose PD
    Gut Microbial Dysbiosis in the Pathogenesis of Leukemia: An Immune-based Perspective.
    Exp Hematol. 2024 Mar 23:104211. doi: 10.1016/j.exphem.2024.104211.
    PubMed         Abstract available

    Int J Hematol

  13. NAKAMURA T, Oya S, Ozawa H, Maehiro Y, et al
    Correlation of ex vivo and in vivo ammonia production with L-asparaginase biological activity in adults with lymphoid malignancies.
    Int J Hematol. 2024;119:426-431.
    PubMed         Abstract available

  14. XU J, Zong S, Sheng T, Zheng J, et al
    Rapamycin increases leukemia cell sensitivity to chemotherapy by regulating mTORC1 pathway-mediated apoptosis and autophagy.
    Int J Hematol. 2024 Mar 26. doi: 10.1007/s12185-024-03732.
    PubMed         Abstract available

  15. USUKI K, Miyamoto T, Yamauchi T, Ando K, et al
    A phase 1/2 study of NS-87/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia.
    Int J Hematol. 2024 Mar 26. doi: 10.1007/s12185-024-03733.
    PubMed         Abstract available

    J Biol Chem

  16. KANEFSKY J, Basse M, Sokei J, di Martino O, et al
    J Biol Chem. 2024 Mar 22:107214. doi: 10.1016/j.jbc.2024.107214.
    PubMed         Abstract available

    J Clin Oncol

  17. RUSSELL NH, Wilhelm-Benartzi C, Othman J, Dillon R, et al
    Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations.
    J Clin Oncol. 2024;42:1158-1168.
    PubMed         Abstract available

    J Natl Cancer Inst

  18. HANTEL A, Brunner AM, Plascak JJ, Uno H, et al
    Race/ethnic associations with comprehensive cancer center access and clinical trial enrollment for acute leukemia.
    J Natl Cancer Inst. 2024 Mar 22:djae067. doi: 10.1093.
    PubMed         Abstract available

    J Pediatr Hematol Oncol

  19. DEVINE KJ, Trivedi H, Reilly AF
    B-Lymphoblastic Lymphoma in Children: A Case Series From a Single Institution.
    J Pediatr Hematol Oncol. 2024;46:e254-e258.
    PubMed         Abstract available

    Leuk Lymphoma

  20. CORTES J, Jonas BA, Schiller G, Mims A, et al
    Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML).
    Leuk Lymphoma. 2024 Mar 27:1-8. doi: 10.1080/10428194.2024.2333451.
    PubMed         Abstract available

  21. MATTHEWS A, Fenu E, Skuli SJ, Harris JC, et al
    Immunohistochemistry-based detection of TP53 mutations in acute myeloid leukemia: a promising high sensitivity diagnostic approach.
    Leuk Lymphoma. 2024 Mar 27:1-4. doi: 10.1080/10428194.2024.2332505.

    Leuk Res

  22. MUTHIAH C, Narra R, Atallah E, Juan W, et al
    Evaluating population-level outcomes in Chronic Lymphocytic leukemia in the era of novel therapies using the SEER registry.
    Leuk Res. 2024;140:107496.
    PubMed         Abstract available

  23. SMITH BD, Brummendorf TH, Roboz GJ, Gambacorti-Passerini C, et al
    Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study.
    Leuk Res. 2024;139:107481.
    PubMed         Abstract available


  24. BRIOLI A, Lomaia E, Fabisch C, Sacha T, et al
    Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry.
    Leukemia. 2024 Mar 28. doi: 10.1038/s41375-024-02204.
    PubMed         Abstract available

  25. DE CAMARGO MAGALHAES ES, Hubner SE, Brown BD, Qiu Y, et al
    Proteomics for optimizing therapy in acute myeloid leukemia: venetoclax plus hypomethylating agents versus conventional chemotherapy.
    Leukemia. 2024 Mar 26. doi: 10.1038/s41375-024-02208.
    PubMed         Abstract available

  26. KANTARJIAN H, Branford S, Breccia M, Cortes J, et al
    Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?
    Leukemia. 2024 Mar 26. doi: 10.1038/s41375-024-02229.

  27. BURMEISTER T, Stroh AS, Kehden B, Trautmann H, et al
    Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia.
    Leukemia. 2024 Mar 22. doi: 10.1038/s41375-024-02209.

  28. FARROKHI A, Atre T, Rever J, Fidanza M, et al
    The Emu-Ret mouse is a novel model of hyperdiploid B-cell acute lymphoblastic leukemia.
    Leukemia. 2024 Mar 22. doi: 10.1038/s41375-024-02221.
    PubMed         Abstract available

    PLoS One

  29. SUN K, Tian X, Xia J, Li Q, et al
    Promoting leisure functions through setting creative linguistic landscapes in recreational zones.
    PLoS One. 2024;19:e0299775.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.